|

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

RECRUITINGPhase 2Sponsored by Merck Sharp & Dohme LLC
Actively Recruiting
PhasePhase 2
SponsorMerck Sharp & Dohme LLC
Started2025-04-16
Est. completion2029-03-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations22 sites

Summary

Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH that is caused by heart failure with preserved ejection fraction (HFpEF). Researchers want to know if the study treatment, sotatercept, can treat people with Cpc-PH caused by HFpEF. This is an extension study, which means people who took part in a certain study on sotatercept for Cpc-PH (called a parent study) may be able to join this study. In this extension study, people will take sotatercept and researchers will follow their health for a longer time. The main goal of this extension study is to learn about the long-term safety of sotatercept and if people tolerate it over a longer period of time.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

\- Completed MK-7962-007 (CADENCE) (Visit 9 and end of treatment \[EOT\] visit) without discontinuing study intervention and is able to safely enroll into MK-7962-007 (HARMONIZE)

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has a diagnosis of pulmonary hypertension (PH) in world health organization (WHO) Group 1, WHO Group 3, WHO Group 4, or WHO Group 5
* Has had a study intervention interruption
* Is pregnant or breastfeeding
* Has chronic liver disease with severe hepatic impairment and/or cirrhosis (eg, hepatic encephalopathy)
* Anticipation of more than 1 valve replacement or repair (mechanical or biomechanical) and/or have undergone more than 1 valve replacement or repair
* Has severe tricuspid regurgitation due to primary valvular disease (eg, from endocarditis, carcinoid, or mechanical destruction)
* Anticipated or undergone heart transplant or ventricular assist device implantation
* Has had prior exposure to luspatercept

Conditions2

Heart DiseaseHypertension, Pulmonary

Locations22 sites

Pulmonary Associates, PA ( Site 1008)
Phoenix, Arizona, 85032
Study Coordinator602-346-4742
Jeffrey S. Sager, MD Medical Corporation ( Site 1060)
Santa Barbara, California, 93105
Stanford University Medical Center ( Site 1024)
Stanford, California, 94305
South Denver Cardiology Associates ( Site 1091)
Littleton, Colorado, 80120
Yale New Haven Hospital ( Site 1093)
New Haven, Connecticut, 06520
Study Coordinator203-495-2410

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.